Corporate News
Page 7
Nov 08, 2017
REPROCELL Chooses Science Exchange as the Preferred Partner to Increase Accessibility of its Predictive Drug Discovery Services
PALO ALTO, CA, November 8, 2017 – Science Exchange, the world’s leading and most secure enterprise platform for outsourced research services and procurement of human biospecimens, announced today that REPROCELL has selected the Science Exchange platform.
Sep 27, 2017
Article by Dr David Bunton (co-authored) in the European Pharmaceutical Review, Autumn 2017
REPROCELL Europe Ltd’s CEO, Dr David Bunton, has co-authored an article titled New Strategy that has been published in the European Pharmaceutical Review, Autumn 2017.
Aug 10, 2017
Nicola Sturgeon: interview at the official opening of REPROCELL’s Centre for Predictive Drug Discovery (YouTube video)
Video: First Minister Nicola Sturgeon officially opened the new European headquarters of a life sciences company which is set to generate 15 new jobs and safeguard a further three following new investment.
Aug 10, 2017
Press Release: Nicola Sturgeon, First Minister of Scotland, opens REPROCELL European Headquarters in Glasgow
REPROCELL Europe Ltd (REPROCELL), a leading provider of products and services for research in stem cells, drug discovery, human tissues and 3D cell culture and a member of the REPROCELL Group, has opened its European headquarters in Glasgow, UK.
May 24, 2017
REPROCELL and Fox Chase Cancer Center Partner to Open Multi-Site Biosample Repository in India
REPROCELL and Fox Chase Cancer Center today announced a joint venture to open a multi-site bio-sample repository facility in India.
Apr 13, 2017
REPROCELL and Fox Chase Cancer Center Form Strategic Alliance to Accelerate Biomarker and Genetic Discovery
REPROCELL and Fox Chase Cancer Center have announced a strategic alliance aimed at accelerating oncology discovery and translational studies, read more
Mar 03, 2017
REPROCELL Europe’s CEO Dr David Bunton presented at NC3Rs workshop: Human tissue models for cancer research
REPROCELL Europe’s CEO, Dr David Bunton presented at the recent NC3Rs meeting on the use of human tissues in cancer research. The conference considered the potential for human tissue models to help reduce clinical drug attrition and provide more relevant models of cancer
Feb 14, 2017
REPROCELL Inc CEO meets with Scottish Cabinet Secretary Fiona Hyslop in Japan
Read about the REPROCELL CEO's meeting with Fiona Hyslop, Cabinet Secretary for Culture, Tourism and External Affairs for the Scottish Government
Feb 07, 2017
Scottish Enterprise Association Honours REPROCELL with Annual Awards Nomination
Read about REPROCELL CEO Dr David Bunton's nomination for the Scottish Enterprise Association Life Science Business Leadership Award
Jan 13, 2017
Prof Stefan Przyborski to chair the SMi Group’s 3D Cell Culture 2017 Conference (22-23 Feb)
The SMi Group’s 3D Cell Culture 2017 Conference (22-23 Feb) will be chaired by REPROCELL Europe’s chief scientific officer (CSO), Professor Stefan Przyborski. He will also be giving the first lecture in the conference.
Nov 22, 2016
Notice of formation of contract with Healios K.K. for testing services for regenerative pharmaceutical products
REPROCELL announces an entrustment contract with Healios K.K. for sample testing support of human clinical trials conducted by Healios.
Nov 16, 2016
Notice of formation of contract with FANCL Corp. for human iPS cell-derived model cell development
Today, REPROCELL announces the formation of a technology development agreement and entrustment contract with FANCL Corp. for the development of a 3D model system derived from human iPS cells.
Nov 11, 2016
Announcement on the initiation of a new business from the collaboration and commercialization agreement with Steminent Biotherapeutics Inc. for cell therapy
Read about REPROCELL's partnership with Steminent Biotherapeutics to develop and commercialize Steminent’s allogeneic stem cell therapy product Stemchymal.
Sep 16, 2016
REPROCELL Europe wins CV Technology Innovator Awards 2016 for Alvetex
REPROCELL Europe has won the Corporate Vision Technology Innovation Award 2016 for Alvetex technology for 3D cell culture.
Jul 06, 2016
Prof Stefan Przyborski speaking at BBS 2016 Biennial Meeting
ReproCELL Europe Ltd’s Chief Scientific Officer Prof Stefan Przyborski is giving a public lecture on “Scaffold Cell Culture Technology for Generation of In Vivo-like Tissue Models” at the British Biophysical Society 2016 Biennial Meeting 6th-8th July, University of Liverpool, Liverpool, UK.
May 20, 2016
REPROCELL Europe’s (formerly Reinnervate’s) CSO Prof Stefan Przyborski to give an Alvetex Seminar at the University of Oxford, 24 May 2016
Professor Stefan Przyborski, Chief Scientific Officer of REPROCELL Europe (formerly Reinnervate), is to give a seminar on Alvetex next week, 24th May 2016.
May 13, 2016
Latest Proteon and Biopta publication demonstrates Proteon's Vonapanitase effects in human cephalic veins
Proteon Therapeutics Announces Publication in Cardiovascular Pharmacology: Open Access Describing Promising Nonclinical Results for Vonapanitase in Improving Arteriovenous Fistula (AVF) Maturation and patency in Chronic Kidney Disease (CKD) Patients.
Apr 21, 2016
Proteon and Biopta publication shows promising nonclinical results on Proteon's Vonapanitase
Proteon Therapeutics Announces Publication in the Journal of Cardiovascular Pharmacology of Promising Nonclinical Results for Vonapanitase in Peripheral Artery Disease.
Mar 22, 2016
Reinnervate Ltd wins Corporate Vision’s 2015 Technology Innovator Award for Alvetex
We are pleased to announce that Reinnervate Ltd has been awarded Corporate Vision’s 2015 Technology Innovator Award for Alvetex 3D cell culture. Alvetex has been awarded the title, “Most Advanced 3D Cell Technology.”
Jan 14, 2016
Alvetex in Space
While the first British ESA astronaut Tim Peake is currently on the International Space Station (ISS) and is about to make his first spacewalk, now is a good time to mention again that Reinnervate’s flagship product, Alvetex® Scaffold, has been used as part of a BBSRC-funded project on the ISS in recent months.